Consistent with this notion, pharmacological activation of ERp57 using Disogenin significantly reduced amyloid plaques and neurofibrillary tangles in the cerebral cortex and hippocampus of a mouse model of AD, in which five familial AD human APP mutations were co-expressed (Tohda et al., 2012). This evidence concerns the gene APP and Alzheimer disease.